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ABSTRACT
Objectives To evaluate (i) the association between
random certolizumab drug levels, antidrug antibodies
(ADAbs) and treatment response in patients with
rheumatoid arthritis (RA); (ii) longitudinal factors
associated with ADAbs and certolizumab drug levels.
Methods This prospective cohort included 115 patients
with RA treated with certolizumab. Serum samples were
collected at 3, 6 and 12 months following treatment
initiation. Drug levels and ADAbs were measured using
ELISA and radioimmunoassay, respectively, at 3, 6 and
12 months. Disease Activity Score in 28 joints (DAS28)
were measured at each visit and 12 months European
League Against Rheumatism (EULAR) response was
calculated. Patient self-reported adherence was collected
longitudinally. Ordinal logistic regression and generalised
estimating equation were used to test the association: (i)
between drug levels, from serum sampled and treatment
response; (ii) between ADAbs and drug levels; (iii)
patient-centred factors and drug levels.
Results ADAbs were detected in 37% (42/112 patients
by 12 months). The presence of ADAbs were significantly
associated with lower drug levels over 12 months
(β=−0.037, 95% CI −0.055 to 0.018, p<0.0001) but
not independently with 12 months EULAR response
(β=0.0013 (95% CI −0.0032 to 0.00061), p=0.18).
Drug level was associated with 12 months EULAR
response (β=0.032 (95% CI 0.0011 to 0.063),
p=0.042). In the multivariate model, ADAb level and
adherence were significantly associated with drug
concentrations.
Conclusions This is the first study to demonstrate that
higher certolizumab drug levels are associated with
better 12 months EULAR response. ADAbs in
certolizumab-treated patients with RA were detected at
higher levels than previous studies and help determine
the aetiology of a low drug level.
INTRODUCTION
Although tumour necrosis factor inhibitor (TNFi)
drugs, such as certolizumab pegol, have been shown
to be efficacious in the treatment of rheumatoid
arthritis (RA), not all patients respond to treat-
ment.1 2 In infliximab, adalimumab and golimumab-
treated patients, absent/reduced treatment response
may be the result of low drug concentrations due to
immunogenicity (formation of antidrug antibodies
(ADAbs)).3–5 ADAbs can reduce drug concentrations
via antibody-mediated drug clearance, and reduce
efficacy by preventing the drug binding to its target.
Certolizumab pegol is a PEGylated Fab’ fragment of
a recombinant humanised antibody directed against
TNF. While PEGylation has been shown to reduce
ADAbs in some proteins,6 it may increase it in
others.7
Initial registration trials in certolizumab-treated
patients with RA revealed low ADAb levels using
an ELISA, ranging 5.1%–6.1%.1 2 In a post hoc
Crohn’s disease trial analysis, higher certolizumab
drug levels were associated with endoscopic
response and remission.8 To date, there have been
no prospective observational studies assessing drug
levels and ADAbs for correlation with treatment
response in certolizumab-treated patients with RA.
The aims of this study were to (i) assess the inci-
dence of ADAbs in certolizumab-initiated patients
with RA using sensitive detection techniques; (ii)
test the association between certolizumab drug
levels, ADAbs and 12 months treatment response in
patients with RA; (iii) assess baseline and longitu-
dinal factors associated with certolizumab drug
levels and ADAb formation.
METHODS
Patients
Certolizumab-initiated patients were recruited to a
prospective observational cohort study, the
Biologics in Rheumatoid Arthritis Genetics and
Genomics Study Syndicate (BRAGGSS), from 60 UK
centres between March 2010 and January 2015.9
From the total cohort, 115 patients were selected,
according to the following inclusion criteria: RA
according to the revised American College of
Rheumatology 1987 criteria,10 active disease indi-
cated by a 28-joint Disease Activity Score (DAS28)
of ≥5.1 despite earlier treatment with at least two
non-biologic disease-modifying antirheumatic drugs
(nbDMARDs) including methotrexate; patients of
Caucasian descent; about to be initiated on subcuta-
neous certolizumab 400 mg every 4 weeks; baseline
visit recorded with ≥1 subsequent visit where serum
samples and clinical data were available.
Following initiation of therapy, patients had
serum samples collected and disease activity
assessed at 3, 6 and 12 months.9 Clinical and
patient questionnaires, including patient self-
reported adherence, were collected at each time
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point. Adherence was classified as previously defined.11
Contributing patients provided written informed consent, and
the study was ethically approved (COREC 04/Q1403/37).
Clinical response
Primary outcome was defined as treatment response at 12 months
using European League Against Rheumatism (EULAR) response
criteria.12 Change in DAS28 C-reactive protein (CRP) (ΔDAS28)
was calculated as the difference between the postinitiation and
pretreatment DAS28CRP scores. To establish a concentration–
effect curve, to determine an optimal drug level cut-off for certoli-
zumab patients with RA, all patients were sorted from high to low
drug levels with correlating ΔDAS28, as described previously.13
Measurement of certolizumab drug levels and ADAbs
The measurement of random certolizumab concentrations was
performed using a sandwich ELISA and ADAbs using radio-
immunoassay (RIA) designed by Sanquin, Amsterdam, The
Netherlands, as previously described for infliximab/adalimumab
patients.14 RIA measures the amount of IgG antibodies specific
for certolizumab. Patients were defined as being positive if
ADAb titres were >20 AU/mL, as specified by cut-off values
generated by Sanquin.
Statistical analysis
Between-group comparisons were investigated using independ-
ent sample t tests, Mann–Whitney U (Wilcoxon) statistics or χ2
tests, as appropriate. Ordinal logistic regression was used to test
the association between EULAR response at 12 months and
drug levels. To assess effect of covariates longitudinally on certo-
lizumab drug and ADAb levels at 3, 6 and 12 months, general-
ised estimating equation (GEE) with an identity link was used.
The multivariate model included significant factors from uni-
variate analysis. The last observation was carried forward for
patients with incomplete data. Statistical analyses were per-
formed using STATA for Windows V.13.0 and Graph Pad Prism
6.04 for concentration–effect curve generation.
RESULTS
Patients
Over 12 months, 253 serial samples (n=115 patients) were
tested for certolizumab drug levels (112 had sufficient sample
for ADAb measurement). ADAbs were detected in 37% (42/112
patients) by 12 months of treatment. The baseline characteristics
of the total patient population and stratified by detectable
ADAbs is shown in table 1. Patients who had detected ADAbs
had significantly higher swollen joint counts at baseline. Six
patients (14.3%) who developed ADAbs, received a prior bio-
logic versus three patients (4.3%) in the group who did not
develop ADAbs. Baseline use and dose of nbDMARDs and oral
steroids did not differ significantly between groups (table 1).
Of the 20 patients who did not complete 12-month
follow-up, 11 (55%) stopped due to inefficacy, 6 (30%) stopped
due to adverse events (AEs), 1 (5%) each stopped due to ineffi-
cacy/AEs, poor adherence (5%) and imminent heart surgery
(5%). Of the patients who experienced AEs, two (one with
recurrent chest infections) had drug levels of >40 μg/mL, two
had drug levels 28–32 μg/mL (exacerbation of chronic
Table 1 Demographic and clinical characteristics at baseline stratified by antidrug antibody status
Baseline characteristics
Total patient
population (n=112)
Patients with antidrug
antibodies detected (n=42)
Patients without antidrug
antibodies detected (n=70) p Value
Age years, mean (SD) 58.0±12 57.3±13 58.5±12 0.30
Female (%) 78 (69.6) 27 (64.3) 51 (72.9) 0.30
BMI (IQR) 27.1 (23.4–32.0) 26.6 (23.5–30.9) 27.9 (23.0–33.6) 0.54
Disease status
Disease duration, median (IQR), years 7.0 (3.3–14.4) 8.3 (5.7–15.3) 6.0 (3.3–12.4) 0.095
RF positivity* (%) 61 (73.4) 23 (76.7) 38 (71.7) 0.62
Erosive disease, n*(%) 34 (48.6) 14 (56.0) 20 (44.4) 0.35
DAS28, mean (SD) 5.9 (0.8) 6.0 (0.9) 5.9 (0.8) 0.26
Tender joint count (28 joints), median (IQR) 17 (10–24) 17 (10–24) 17 (11–23) 0.84
Swollen joint count (28 joints), median (IQR) 9 (6–13) 10 (7–16) 8 (6–12) 0.043
ESR, median (IQR), mm/h 18 (10.0–37.0) 23.0 (12.0–54.0) 16.5 (10.0–31.0) 0.24
C-reactive protein, median (IQR), mg/L 7.5 (3.3–21.0) 8.9 (3.8–24.0) 7.2 (3.22–20.0) 0.57
Patient global score 75 (56–85) 80 (70–86) 75 (54–82.5) 0.25
Prior biologic (%) 9 (8.0) 6 (14.3) 3 (4.3) 0.059
Oral steroids at baseline (%)* 21 (18.7) 5 (18.5) 16 (19.2) 0.68
nbDMARD therapy
Methotrexate use (%) 60 (53.5) 22 (52.4) 38 (54.3) 0.85
Methotrexate dose, median (IQR) mg/week 20 (15–25) 20 (15–25) 20 (15–25) 0.87
Sulfasalazine (%) 17 (15.2) 6 (14.3) 11 (15.7) 0.84
Sulfasalazine
Median (IQR) mg/day
1000 (1000–1000) 1000 (1000–1000) 1000 (1000–1000) 0.75
Leflunomide n (%) 3 (2.7) 1 (2.4) 2 (2.9) 0.88
Hydroxychloroquine (%) 6 (5.3) 2 (4.8) 4 (5.7) 0.83
Baseline nbDMARD use (%) 91 (81.2) 20 (71.4) 71 (84.5) 0.29
*Data for categorical variables is presented as percentage of non-missing data. nbDMARDs listed are the most frequently used in the cohort.
BMI, body mass index; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; nbDMARD, non-biologic disease-modifying antirheumatic drug; RF, rheumatoid
factor.
Bold typeface indicates significance at p<0.05.
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obstructive pulmonary disease symptoms; bilateral pitting
oedema and excessive fatigue, respectively), while one patient
stopped due to feeling generally unwell with drug levels of
0.2 μg/mL (none with ADAbs). The patient who stopped due to
both inefficacy and AEs had drug levels of 2.6 μg/mL and
ADAbs of 70 AU/mL at 6 months. Additional information about
all patients who developed AEs and their pharmacological tests
is provided in online supplementary table S1.
Detection of ADAbs and drug levels
The ADAb titre ranged from 22 to 1600 AU/mL. The presence
of ADAbs were significantly associated with lower drug levels
over 12 months using GEE (β=−0.037, 95% CI −0.055 to
−0.018, p<0.0001), but not independently with 12 months
EULAR response (β=0.0013 (95% CI −0.0032, to 0.00061),
p=0.18). Using ordinal regression, drug level was associated
with 12 months EULAR response (β=0.032 (95% CI 0.0011 to
0.063), p=0.042).
Concentration–effect curve
Figure 1A,B shows concentration–effect curves for
certolizumab-treated patients. There was a trend for higher cer-
tolizumab levels (>23–24 μg/mL) to be associated with improve-
ment in DAS28 from baseline. Patients with the highest
certolizumab drug levels had a higher proportion of EULAR
good responders at 12 months (figure 1C).
In figures 1A/B each point represents the mean ΔDAS28
(point) and SD (error bars) for the certolizumab drug level
range measured at 6 months of treatment stratified in ascending
order. Due to the distribution in drug levels, stratification of
drug concentrations was performed as described in figure 1A.
Figure 1B represents mean ΔDAS28 and SD for deciles gener-
ated from the certolizumab drug level data at 6 months, similar
to previous studies13: (1) 0–10 μg/mL, (2) 11–20 μg/mL, (3) 21–
23 μg/mL, (4) 23–24 μg/mL, (5) 25–29 μg/mL, (6) 29–31 μg/mL,
(7) 31–33 μg/mL, (8) 31–38 μg/mL, (9) 39–46 μg/mL and (10)
>46 μg/mL.
Figure 1 (A) Certolizumab concentration–effect curve at 6 months (using drug-level thresholds). (B) Certolizumab concentration–effect curve at
6 months (deciles). (C) Certolizumab levels in European League Against Rheumatism (EULAR) good, moderate and non-responders at 12 months.
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Figure 1C represents the percentages of EULAR responders
when stratified by serum certolizumab level. The data represents
all 115 patients using last observation carried forward. Patient
numbers in each category are as follows: certolizumab levels
<10 μg/mL: good EULAR response, 7; moderate EULAR
response, 7; no EULAR response, 3; certolizumab levels
10–22.9 μg/mL: good EULAR response, 10; moderate EULAR
response, 9; no EULAR response, 4; certolizumab levels
23–39.9 μg/mL: good EULAR response, 34; moderate EULAR
response, 19; no EULAR response, 5; certolizumab levels
>40 μg/mL: good EULAR response, 11; moderate EULAR
response, 5; no EULAR response, 1.
Baseline and longitudinal factors associated with drug
levels and ADAbs
Factors associated with certolizumab drug level in the univariate
GEE analysis were gender, adherence, body mass index, CRP
and ADAb level (table 2). In the multivariate model after adjust-
ment of confounders, ADAb levels and adherence remained sig-
nificant (table 2). Certolizumab drug concentrations showed a
strong inverse association with certolizumab ADAb level longitu-
dinally over 12 months (table 2).
DISCUSSION
This study demonstrates for the first time that certolizumab
ADAbs were detectable in 37% of patients with RA over
12 months of treatment. Detectable ADAbs were associated with
lower certolizumab drug concentrations, but not independently
with treatment response. However, higher certolizumab drug
levels were associated with better 12 months EULAR response.
Following adjustment, ADAb concentrations and biologic adher-
ence remained the most important predictors of drug levels over
time.
Our data demonstrates that even small, non-glycosylated frag-
ments such as certolizumab can be immunogenic. The higher
levels of ADAbs detected compared with previous certolizumab
trials1 2 is noteworthy. However, in contrast to other biologics,
ADAbs against certolizumab may be detected more easily even
in the presence of drug. Certolizumab is a Fab fragment, mono-
valent, and therefore, drug–ADAb complexes easily dissociate
and can thus be detected despite the drug not necessarily being
more immunogenic. RIA, for the detection of ADAbs, has not
been used in published certolizumab trials to date. Our data sug-
gests potential for clinical application, but further studies are
needed to validate optimal use of the assay in clinical practice.
While not being independently associated with treatment
response, ADAbs showed a strong inverse correlation with circu-
lating certolizumab drug levels. Therefore, detection of ADAbs
need not significantly influence treatment response if sufficient
drug is still in circulation but may provide valuable insight into
the aetiology of low drug levels in certolizumab-treated patients.
Certolizumab drug concentrations reflect the amount of circu-
lating drug available to bind to the target, so measurement of
drug concentrations9 may help in determining the aetiology of
non-response. This is the first study that has found an associ-
ation between detectable ADAbs to certolizumab and drug con-
centrations. Other studies have demonstrated in TNFi treated
patients, a high disease burden at baseline may be associated
with ADAb formation.15 In the current study, pretreatment
swollen joint count was significantly higher in patients with
detectable ADAbs, supporting data that baseline inflammation
may associate with drug concentrations and certolizumab
ADAbs.
A strength of our study is the capture of additional factors
likely to influence treatment response and drug concentrations
in a real-life setting. Of these, adherence was an important
Table 2 Factors associated with drug levels and anticertolizumab antibodies longitudinally over 12 months using GEE
Variable
Certolizumab drug level
β coefficient (95% CI) p Value
ADAb level
β coefficient (95% CI) p Value
Univariate analysis
Age 0.14 (−0.017 to 0.29) 0.08 0.021 (−2.16 to 2.21) 0.99
Female gender* 4.76 (0.21 to 9.29) 0.040 −67.36 (−146.14 to 11.41) 0.094
BMI −0.46 (−0.89 to −0.041)* 0.032 −0.92 (−6.03 to 4.19) 0.72
CRP −0.099 (−0.17 to −0.029)* 0.005 0.57 (−0.32 to 1.47) 0.21
ESR −0.12 (−0.22 to −0.020)* 0.019 0.40 (−0.95 to 1.74) 0.58
Baseline methotrexate use −0.11 (−4.68 to 4.47) 0.96 −3.65 (−53.38 to 46.08) 0.89
Baseline methotrexate dose 0.23 (0.33 to 0.78) 0.43 4.94 (3.74 to −13.6) 0.27
Baseline oral steroid use 3.15 (−1.89 to 8.20) 0.22 −29.77 (−69.54 to 10.0) 0.14
Any nbDMARD use at baseline† 3.15 (−1.89 to 8.20) 0.22 −54.66 (−125.37 to 16.05) 0.14
Antidrug antibody level −0.037 (−0.055 to −0.018)* <0.0001 –
Certolizumab drug level – – −2.56 (−4.09 to −1.03)* 0.001
Adherence 10.43 (4.76 to 16.11)* <0.0001 −45.05 (−108.35 to 18.25) 0.16
Multivariate model‡
Antidrug antibody level −0.044 (−0.059 to −0.028)* <0.0001 –
Adherence 7.08 (0.71 to 13.45)* 0.029 –
Female gender 1.77 (−4.21 to 7.76) 0.56 –
BMI −0.13 (−0.68 to 0.43) 0.65 –
CRP −0.065 (−0.14 to 0.013) 0.102 –
*p<0.05.
†nbDMARD use included methotrexate, sulfasalazine, leflunomide or hydroxychloroquine at baseline.
‡Adjusted for variables significant in the univariate analysis. CRP was used instead of ESR in the multivariate model, as was measured in all patients. In the second column, certolizumab
drug level is used as the dependant variable in the GEE model; in the fourth column, anticertolizumab antibodies are used as the dependant variable in the GEE model.
ADAb, antidrug antibody; BMI, body mass index; ESR, erythrocyte sedimentation rate; GEE, generalised estimating equation; nbDMARD, non-biologic disease-modifying antirheumatic
drug.
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factor influencing certolizumab levels (although CIs were wide,
as non-adherence was infrequently reported). A low certolizu-
mab drug level in the absence of ADAb formation may prompt
a discussion with the patient regarding reasons for non-
adherence, also shown to be important in adalimumab-treated
patients.9 While several TNFi therapeutic drug-monitoring
studies have used trough-level serum samples to measure both
ADAbs and drug levels to reduce drug interference, ascertain-
ment of random levels is clinically practical. We have previously
demonstrated that low random TNFi drug levels in
adalimumab-treated patients have been associated with poor
treatment response in RA over 12 months.9 However, a limita-
tion of our study is that, while 37% of patients had detectable
ADAbs to certolizumab, this may under-represent the true value
due to drug interference.
Whilst our study did not identify a clear drug concentration
cut-off for treatment response in patients with non-trough
samples, higher 6 months certolizumab levels (>23–24 μg/mL)
were associated with higher ΔDAS28. However, four patients
who had an adequate response at 6 and 12 months had
undetectable concentration levels, two of whom had ADAbs
detected. These patients may represent a unique subset, in
which certolizumab could be stopped, avoiding the need for
future treatment with expensive biologics.
In summary, certolizumab drug levels may be useful in thera-
peutic drug monitoring in combination with clinical parameter
assessment. Measurement of ADAbs may facilitate the interpret-
ation of low drug levels and provide valuable information about
future strategy. More information is required, however, on the
cost-effectiveness of using these tests before implementation in
clinical practice.
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